General Description
Hetacillin is a semisynthetic penicillin prodrug derived from ampicillin and acetone via a condensation reaction, forming a stable 2,2‑dimethyl‑5‑oxazolidinecarboxylic acid ring. This heterocyclic structure is acid‑stable and reverts to ampicillin upon hydrolysis in the body. The molecule was developed to improve oral absorption and reduce gastrointestinal side effects compared to ampicillin.
Mechanism of Action
Hetacillin itself has minimal antibacterial activity; it serves as a reservoir that releases ampicillin both in the gut and systemically. The released ampicillin inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins (PBPs), disrupting peptidoglycan cross‑linking. This leads to cell lysis and death of susceptible gram‑positive and gram‑negative organisms. The prodrug approach does not confer resistance to beta‑lactamases.
Application
Hetacillin was indicated for infections caused by susceptible organisms, including respiratory tract infections, urinary tract infections, and skin/soft tissue infections. It has a spectrum identical to ampicillin, covering Streptococcus species, Enterococcus faecalis, E. coli, and Proteus mirabilis.